– May 1, 2011
May 1, 2011
View Issues
-
Outcomes for Patients on Long-term Imatinib Treatment for Chronic Myelogenous Leukemia
In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy. -
Transplant vs Imatinib for Accelerated Phase CML
Limited data are available to guide the decision between up-front allogeneic hematopoietic cell transplantation (HCT) or imatinib on long-term outcomes for accelerated phase chronic myelogenous leukemia (CML). -
Gall Bladder Cancer
A 71-year-old retired police officer was admitted through the emergency room with right upper quadrant pain and low-grade fever. -
Radiofrequency Ablation for Primary and Secondary Malignancy in the Lung
Patients with localized but non-resectable lung cancer generally are considered candidates for other types of therapy including external beam or stereotactic radiation therapy, chemotherapy, or percutaneous ablation. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.